SEOUL, South Korea — Cellid Co., a South Korean biotechnology company listed on the KOSDAQ (299660), announced on July 29, 2025, that its proprietary adenovirus vector platform technology, utilized in its COVID-19 vaccine candidate AdCLD-CoV19-1 OMI, has secured a patent in Europe. The patent pertains to an optimized vector structure designed for the large-scale production of replication-incompetent adenoviruses. This achievement follows similar patent approvals in South Korea, the United States, China, Japan, and Russia, with applications still under review in Vietnam, Indonesia, Thailand, a
Medicine
Kim Kuk Ju, HEALTH IN NEWS TEAM
2025.07.31 16:39
